April 28, 2020 / 1:13 PM / a month ago

BRIEF-Obalon Gas-Filled Balloon Not Subject Of Fourth FDA Letter To Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons

April 28 (Reuters) - Obalon Therapeutics Inc:

* OBALON GAS-FILLED BALLOON NOT SUBJECT OF FOURTH FDA LETTER TO HEALTH CARE PROVIDERS RELATED TO SERIOUS RISKS, INCLUDING DEATH, WITH LIQUID-FILLED INTRAGASTRIC BALLOONS

* OBALON THERAPEUTICS - BELIEVE OBALON BALLOON PERFORMS DIFFERENTLY THAN LIQUID-FILLED BALLOONS CITED IN MOST RECENT FDA LETTER TO HEALTHCARE PROVIDERS

* OBALON - REPORTED TO FDA RESULTS OF 141 PATIENTS TO FINISH THERAPY IN FDA-REQUIRED POST-APPROVAL STUDY, WITH NO DEVICE-RELATED SERIOUS ADVERSE EVENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below